Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totaling 352 shares, a drop of 83.8% from the December 15th total of 2,177 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 32,280 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 32,280 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on BOLT shares. Zacks Research downgraded shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. HC Wainwright set a $7.00 price target on shares of Bolt Biotherapeutics and gave the company a “buy” rating in a report on Monday, October 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $34.00.

Hedge Funds Weigh In On Bolt Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC lifted its stake in Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after purchasing an additional 2,448 shares in the last quarter. Shay Capital LLC purchased a new stake in shares of Bolt Biotherapeutics in the 3rd quarter valued at $85,000. Finally, Susquehanna International Group LLP acquired a new position in Bolt Biotherapeutics during the 3rd quarter worth about $89,000. 86.70% of the stock is owned by hedge funds and other institutional investors.

Bolt Biotherapeutics Stock Up 3.1%

Shares of BOLT traded up $0.18 during midday trading on Tuesday, hitting $5.99. 28,366 shares of the company’s stock traded hands, compared to its average volume of 15,546. The company has a current ratio of 3.57, a quick ratio of 3.57 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $11.50 million, a price-to-earnings ratio of -0.27 and a beta of 0.91. Bolt Biotherapeutics has a 1 year low of $4.41 and a 1 year high of $11.70. The firm’s fifty day moving average is $5.22 and its 200-day moving average is $5.47.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Wednesday, November 12th. The company reported ($3.72) EPS for the quarter, topping analysts’ consensus estimates of ($5.07) by $1.35. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $0.82 million. As a group, sell-side analysts anticipate that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.